Largest BioTech Public Companies in Netherlands

Company	HQ	Description	Sectors	Stock Price	1Y Perf.	Market Cap	EV	EV/Revenue	EV/EBITDA
NewAmsterdam Pharma		NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company wi…NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.	Biopharmaceuticals	$22	-43%	$2.6B	$1.9B	86.4x	(8.4x)
Pharvaris		Pharvaris NV is a late-stage biopharmaceutical company which is engage…Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.	Biopharmaceuticals	$31	+42%	$2.2B	$1.8B	-	(9.0x)
uniQure		uniQure NV is a gene therapy company. It develops treatments and platf…uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.	Biopharmaceuticals	$23	-66%	$1.6B	$817M	50.8x	(6.1x)
Corbion		Corbion NV is a Netherlands-based company that produces food ingredien…Corbion NV is a Netherlands-based company that produces food ingredients and biobased chemicals. The company distinguishes between the segments Functional Ingredients & Solutions and Health & Nutrition. It provides solutions for food preservation, health, and bioplastics through fermentation technology. Its products serve industries including food, pharmaceuticals, personal care, and packaging. Corbion focuses on innovation and sustainability to preserve food, health, and the planet. Geographically, it operates in The NEtherlands, Rest of EMEA, USA, Rest of Americas, and Asia, and derives a majority of its revenue from the U.S.	Bioindustrials	$25	+21%	$1.4B	$2B	1.4x	9.1x
Pharming		Pharming Group is a biotechnology company focused on developing and co…Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.	Biopharmaceuticals	$1	-28%	$671M	$627M	1.7x	18.7x
ProQR Therapeutics		ProQR Therapeutics NV is a biopharmaceutical company. It discovers and…ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.	Biopharmaceuticals	$2	-41%	$230M	$114M	6.4x	(2.5x)
Median				$22	-34%	$1.5B	$1.3B	6.4x	(4.3x)

Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.